Wei Xin, Cao Weihua, Wang Shiyu, Zhang Yaqin, Gao Zixuan, Wang Shuojie, Yao Linmei, Zhang Ziyu, Li Xinxin, Deng Wen, Xie Yao, Li Minghui
Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, 100015, People's Republic of China.
Int J Nanomedicine. 2025 Mar 3;20:2623-2643. doi: 10.2147/IJN.S509409. eCollection 2025.
In recent years, nanobiotechnology, widely used in hepatoma, holds great promise for improving targeted hepatocarcinoma therapy. On account of the unique properties of low toxicity, good tolerance, biocompatibility, and biodegradability of new nanomaterials, a targeted drug delivery system (TDDS) has been constructed, which can boost the therapeutic effect of hepatoma-targeted drugs, reduce drug toxicity, and minimize off target reactions by enhancing permeability retention effect (EPR) and active targeting, thus improving existing liver cancer targeted therapy strategies. Different nanoparticles have their own advantages and disadvantages. They can be loaded with multiple drugs on the same nanoparticle and can also be surface modified with each other to achieve synergistic anti-tumor effects. This essay provides a comprehensive overview of the current status of targeted therapy for hepatocarcinoma, nanoparticles' structure, advantages and disadvantages of each nanoparticle, and the application progress of nanoparticles in targeted therapy for liver cancer. We hope to provide a basis for the future clinical targeted therapy of hepatoma using nanotechnology.
近年来，纳米生物技术在肝癌治疗中广泛应用，有望改善肝癌的靶向治疗。鉴于新型纳米材料具有低毒性、良好耐受性、生物相容性和可生物降解性等独特特性，构建了一种靶向给药系统（TDDS），该系统可通过增强渗透滞留效应（EPR）和主动靶向作用，提高肝癌靶向药物的治疗效果，降低药物毒性，并使脱靶反应最小化，从而改进现有的肝癌靶向治疗策略。不同的纳米颗粒有各自的优缺点。它们可以在同一纳米颗粒上负载多种药物，也可以相互进行表面修饰以实现协同抗肿瘤效果。本文全面综述了肝癌靶向治疗的现状、纳米颗粒的结构、每种纳米颗粒的优缺点以及纳米颗粒在肝癌靶向治疗中的应用进展。我们希望为未来利用纳米技术进行肝癌临床靶向治疗提供依据。
